How to Evaluate a Private Equity Offer for an ABA Practice

To evaluate a private equity offer for an ABA practice, move past the headline valuation and reconstruct the whole arrangement: cash at closing, debt and transaction costs, working capital, escrow, earnout, rollover equity, taxes, governance rights, employment terms, clinical independence, buyer financing, future exit assumptions, and the effect on employees and families. Diligence the buyer as seriously as the buyer diligences the practice. A strong offer is one you understand in ordinary operating scenarios as well as in the optimistic presentation.

The headline number is only the front door

A private equity conversation can move from flattering to disorienting in a few days. An owner hears a multiple, imagines relief from years of personal risk, and then receives a proposal full of unfamiliar terms. The number may be real, but it is not the same as cash the owner keeps, freedom from future obligations, or a better operating home for the practice.

Learning how to evaluate a private equity offer for an ABA practice begins by slowing the story down. Ask what is being sold, who is buying it, how the purchase will be financed, what the owner receives at closing, what remains contingent, and who controls the practice afterward. Put every answer in writing. A warm relationship with the deal team can coexist with a structure that is difficult for the seller, employees, or families.

Build a small circle that can disagree with the deal

Choose advisers before the timetable becomes urgent. Transaction counsel, a tax adviser, an accountant or quality-of-earnings professional, and an ABA operator who understands payer and clinical realities see different risks. The practice's qualified privacy, security, employment, benefits, insurance, and clinical leaders may also need bounded roles. Define who can see which material, how conflicts are disclosed, and who is paid only if the deal closes.

The SBA sale guidance recommends qualified advice, valuation, and a comprehensive sales agreement. That is broad small-business orientation, not a substitute for healthcare transaction counsel. Ask each adviser to explain the downside in plain language. If everyone is rewarded by closing, appoint someone whose job is to test whether remaining independent or waiting is genuinely better.

Rebuild value from the practice you actually operate

Buyers often begin with adjusted earnings. Some adjustments are sensible, such as a one-time expense. Others assume that an owner's duties disappear, a position can stay vacant, collections will improve, or growth will arrive without the people and cash required to deliver it. Reconcile every adjustment to the general ledger, payroll, deposits, contracts, and work that someone will still have to perform.

Then inspect concentration and durability. Which payers, locations, clinicians, referral sources, owners, and service lines create the result? How much revenue is authorized but not delivered, billed but not deposited, or dependent on a temporary staffing pattern? A valuation is easier to trust when the owner can trace it back to ordinary weeks and explain what would happen after a resignation, rate change, recoupment, authorization delay, or slower hiring season.

Trace the purchase price all the way to usable proceeds

Rewrite the term sheet as a waterfall. Start with the headline price, then separate cash at closing, debt payoff, transaction expenses, escrow or holdback, working-capital adjustment, seller note, earnout, indemnity exposure, rollover investment, and estimated taxes. Mark when each amount could be received, reduced, delayed, or lost. Do not count rollover equity as cash or an earnout at its maximum until the conditions are understood.

The IRS sale-of-a-business page explains that a business sale usually involves multiple assets and that different asset classifications can receive different tax treatment. Buyer and seller may also have reporting and allocation responsibilities. That does not answer the tax result for a stock sale, asset sale, partnership interest, rollover, earnout, or a specific owner. A qualified tax adviser should model the actual structure before the owner compares offers on an after-tax basis.

Read governance as if the first disagreement has happened

A seller may keep a meaningful ownership percentage and still lose practical control. Read board composition, voting thresholds, reserved matters, budget approval, debt authority, capital calls, distributions, hiring and termination rights, compensation changes, acquisitions, new locations, related-party arrangements, clinical-governance protections, information rights, and amendment powers. Notice which rights expire when the founder's employment ends or ownership falls below a threshold.

The current Merger Guidelines are nonbinding descriptions of federal agency enforcement practice, not individualized legal advice. Their discussion of partial ownership recognizes that minority interests can bring board, information, financing, or operational influence. The practical lesson is not that every minority deal is unlawful. It is that ownership percentage alone does not tell you who can influence capital, strategy, sensitive information, or daily decisions.

Treat rollover equity as a new investment decision

Rollover is often presented as a second opportunity to benefit when the larger platform sells. It may also be illiquid, subordinated, diluted, subject to different security classes, affected by acquisition debt, or tied to continued employment. Ask what entity you will own, what sits above and below it, how value is calculated, which fees leave the business, what information you receive, and whether you can transfer or redeem the interest.

Model several futures: strong growth, flat performance, a delayed exit, a recapitalization, more debt, an employment departure, a capital call, and a sale at a lower multiple. Request the governing documents rather than relying on a capitalization-chart slide. If the offer requires the owner to invest again, the owner deserves investor-quality diligence on the fund, platform, debt, governance, and exit waterfall.

Diligence the buyer behind the polished process

Meet operating leaders, not only the people who source transactions. Ask which fund is investing, the fund's term, capital reserved for the plan, lending constraints, acquisition history, leadership turnover, compliance events, payer disputes, litigation, cybersecurity incidents, and how earlier sellers describe life after closing. Speak privately with founders whose deals went well and founders whose deals did not.

If the strategy depends on repeated acquisitions, understand how the buyer evaluates local competition and integration capacity. DOJ Merger Guideline 8 says agencies may examine the cumulative effect of a pattern or strategy of multiple acquisitions. That does not predict review of a particular ABA transaction. It does mean a buyer's broader acquisition pattern belongs in legal diligence instead of being dismissed because one practice seems small on its own.

Ask what the operating model rewards under pressure

The central question is not whether the buyer says quality matters. Ask what happens when clinical capacity limits starts, an authorization is delayed, a clinician recommends fewer or different hours, a location misses budget, or documentation needs correction before billing. Review incentives for executives, regional leaders, recruiters, clinicians, and revenue-cycle staff. Look for routes that allow qualified professionals to raise concerns without having to defeat a growth target.

The 2024 FTC, DOJ, and HHS health care transaction inquiry sought information about corporate and private-equity transactions, including behavioral-health providers, and raised questions about effects on patients, workers, quality, cost, and competition. An inquiry is not a finding that every private-equity investment causes harm. It is a clear reason to test the actual incentives and safeguards rather than treating capital and quality as automatically aligned.

Keep clinical responsibility visible through the deal

Map assessment, treatment planning, service intensity, supervision, documentation, family involvement, continuity, transition, and discharge authority before and after closing. The BACB Ethics Code applies to people within its scope and addresses truthfulness, competence, conflicts, documentation, client welfare, third-party contracts, supervision, continuity, and transition. It does not approve a transaction or govern a corporation by itself.

Ask how a clinician can decline an unsafe workload, challenge a metric, document a disagreement, or escalate interference. Examine who appoints clinical leadership, which decisions require qualified review, and how the board sees quality without turning clinical records into a financial shortcut. A clause labeled clinical independence is useful only when roles, access, reporting, incentives, and escalation make it workable.

Limit transaction access to what the law and purpose support

Deal diligence can create a rush for data. Build a request log showing the purpose, field, cohort, requester, recipient, authority, minimum necessary determination where applicable, access period, and deletion or return plan. Use de-identified, aggregated, or redacted information when it answers the question. Keep a secure room, individual access, export logs, and a process for unusual requests.

The current definition of health care operations in 45 CFR 164.501 includes certain sale, transfer, merger, consolidation, and related due-diligence activity when the entities meet the stated covered-entity conditions. That is not blanket permission to disclose every record to any bidder, lender, consultant, or affiliate. Counsel and qualified privacy and security leaders should assess each party, purpose, agreement, data set, and transfer route.

Picture an ordinary Tuesday after closing

Willow Lane ABA is fictional. Its founder receives two offers with the same headline value. One has more cash at closing but broad budget vetoes, an aggressive earnout, and no clear answer about regional clinical leadership. The other has less cash, a smaller rollover, clearer reserved rights, and a funded plan for claims cleanup and supervision. When advisers build the waterfall, the apparent gap narrows. When managers rehearse a hiring delay and a denied expansion budget, the governance difference becomes larger.

The founder does not choose from a spreadsheet alone. She meets prior sellers, reads the rollover documents, tests data-access requests, asks clinicians to review the post-close authority map, and compares both offers with a no-sale plan. The final decision record explains which risks are accepted, which protections are contractual, and which hopes remain only assumptions.

Give yourself permission to pause

Set a review calendar that leaves time for unanswered questions, revised documents, financing changes, buyer diligence, and employee or family planning where appropriate. Name stop conditions: unreliable sources for adjusted earnings, a waterfall no one can explain, missing governing documents, unresolved clinical-control conflicts, unsupported PHI requests, buyer references that cannot be reconciled, or pressure to promise a closing before material review is complete.

The OIG General Compliance Program Guidance is voluntary and nonbinding. Its emphasis on leadership, risk assessment, communication, reporting, auditing, incentives, investigation, and corrective action can help an owner examine the future compliance environment. It does not bless a buyer, valuation, fee, referral, ownership arrangement, or transaction. A deliberate no, not yet, or narrower deal can be a successful outcome of good diligence.